



ENDORSEMENTS

DR. Y.K. GUPTA

HEAD DEPARTMENT OF PHARMACOLOGY, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI

“Dengue is an important India specific health problem with worrisome morbidity and mortality. Finding solution to it by Indian laboratories through a drug of plant origin which is grown in India is a matter of pride for all of us. It is great satisfaction that the initial lead identified by collaborative efforts of Ranbaxy, ICGEB, and AIIMS under DBT is now being taken up by Sun Pharma and ICGEB joint collaboration for logical conclusion in the form of a product for management of dengue. CIPA has potential for reducing viral load of all four dengue variants, has antipyretic and anti-inflammatory effect, no effect on platelet, does not adversely affect hematological parameters and favourably effects leukotrine profile. Thus has unique USP. I wish the scientific collaboration of Sun Pharma and ICGEB a great success and I am sure India will soon have an effective and affordable drug for dengue.”

DR. RAM VISHWAKARMA

DIRECTOR, INDIAN INSTITUTE OF INTEGRATIVE MEDICINE, JAMMU

“The discovery of CIPA presents a unique opportunity to develop this as a first-in-class drug for dengue addressing a major recurring disease in India and elsewhere. This could be positioned as one of the first products for clinical development under newly approved regulatory pathway for ‘Phytopharmaceutical Drugs’ by DCGI, as well as the ‘Botanical Drugs’ category of USFDA. I am really excited about contributing towards its successful development.”

DR. RAVIKUMAR BANDA

CEO XCYTON DIAGNOSTICS, BANGALORE

“The importance of Dengue in India cannot be overstated! While the public health initiatives to reduce the mosquito population or vaccination is laudable, frightening clinical complications among the helpless poor who are already infected require a therapeutic intervention. CIPA discovery / invention is therefore significant on in three counts - Firstly, it brings focus to the treasure trove of medicinal plants exploited in ancient India; Secondly, it is antiviral and the most important it seems to regulate the human immune system which has gone out of control during Dengue infection. Finally, It is a proud moment for whole Indian science! I congratulate and commend Sun Pharma for starting clinical program to develop Cipa as botanical drug for Indian and global market”



**DR. ANIT SHET, PROFESSOR OF PEDIATRICS, ST. JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES
BANGALORE, INDIA AND ASSOCIATE SCIENTIST, INTERNATIONAL VACCINE ACCESS CENTER
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, BALTIMORE, USA**

"Dengue is a serious global disease that knows no geographical and economic borders, and has no known cure. India has an exceptional opportunity to contribute to world health by developing this promising locally grown herbal product. Cipa extract has shown excellent anti-viral activity against all four dengue serotypes in laboratory studies, and has a good safety profile in animal studies. Now, the Indian government and industry, prominent scientists and physicians have joined hands in a historical collaborative effort to begin human studies. As a mother of a child with dengue recently told me when we finally discharged her child from the hospital after a harrowing course, 'There must be a medicine in nature to counter this scourge – look hard and you will find it!' The team is doing just this."

PROFESSOR K. VIJAYRAGHAWAN

SECRETARY DEPARTMENT OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, NEW DELHI.

"Dengue is a global public health threat and India represents ~50% of the global population estimated to be at risk of dengue. I am delighted to learn that the DBT initiated research efforts on finding an affordable solution to dengue menace, using Ayurveda based and bioassay guided approaches, are now being taken forward by Sun Pharma and ICGEB. This may be of practical relevance to a dengue-endemic resource-poor country such as India."